Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel

Area of Science:

• Neurology
• Geriatrics
• Clinical Pharmacy

Background:

• Current UK guidance for Parkinson's disease (PD) treatment initiation and therapy selection emphasizes individualized patient care.
• National Institute for Health and Care Excellence (NICE) guidelines recommend comprehensive discussions covering clinical circumstances, lifestyle, preferences, goals, and treatment risks/benefits.
• Individualized management significantly enhances patient outcomes and quality of life in PD.

Purpose of the Study:

• To provide practical guidance for clinicians on managing common, often overlooked, co-morbidities in people with Parkinson's (PwP).
• To identify key areas for improving clinical care through standardized management of co-existing conditions in PD patients.

Main Methods:

• A multi-disciplinary expert roundtable discussion informed by clinical experience and existing literature.
• The meeting was organized and funded by Bial Pharma UK Ltd.
• Experts identified and prioritized four core areas for improved PD management.

Main Results:

• Four core co-morbidity areas were identified: bone health, cardiovascular risk, anticholinergic burden, and sleep quality.
• Standardizing the management of these areas is expected to improve treatment outcomes for PwP.
• Focusing on these areas contributes to personalizing PD treatment regimens and enhancing overall patient well-being.

Conclusions:

• Addressing specific co-morbidities in PD can significantly contribute to personalized patient care.
• The identified guiding factors aim to assist practitioners in optimizing the management of people with Parkinson's.
• Improved management of bone health, cardiac risk, sleep, and anticholinergic burden is key to enhancing patient outcomes.